Navigation Links
Ardea Biosciences to Present at Two Upcoming Investor Conferences
Date:5/4/2011

SAN DIEGO, May 4, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that Barry D. Quart, PharmD, president and chief executive officer, will present at the following upcoming investor conferences:

  • Tenth Annual JMP Securities Research Conference in San Francisco, CA. Presentation: 9:30 a.m. PDT on Monday, May 9, 2011.
  • Bank of America Merrill Lynch 2011 Healthcare Conference in Las Vegas, NV. Presentation: 1:00 p.m. PDT on Tuesday, May 10, 2011.

About Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases. Lesinurad (RDEA594), our lead product candidate for the treatment of hyperuricemia and gout, is a once-daily, oral inhibitor of the URAT1 transporter.  We have completed Phase 2b clinical studies of lesinurad and continue to advance the drug in longer term extensions in preparation for Phase 3 development.  Our next-generation URAT1 inhibitor program is currently in preclinical development. BAY 86-9766 (RDEA119), is a potent and specific inhibitor of mitogen-activated ERK kinase (MEK) for the treatment of cancer being developed under a global license agreement with Bayer HealthCare AG. BAY 86-9766 is currently in a Phase 2 study in patients with hepatocellular carcinoma in combination with sorafenib (Nexavar®; Bayer, Onyx Pharmaceuticals) and a Phase 1/Phase2 study in patients with advanced pancreatic cancer in combination with gemcitabine.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Such statements include, but are not limited to, statements regarding our plans and goals, the expected properties and benefits of lesinurad, BAY 86-9766 (RDEA119) and our other compounds and the timing and results of our preclinical, clinical and other studies.  Risks that contribute to the uncertain nature of the forward-looking statements include risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, costs associated with our drug discovery and development programs, and risks related to the outcome of our business development activities, including collaboration or license agreements.  These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors."  All forward-looking statements contained in this press release speak only as of the date on which they were made.  We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

(Logo:  http://photos.prnewswire.com/prnh/20091104/ARDEALOGO)


'/>"/>
SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ardea Biosciences Earns $15 Million Payment from Bayer HealthCare AG for Achievement of Important Clinical Milestone in Ongoing Collaboration
2. Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
3. Ardea Biosciences to Present at Four Upcoming Investor Conferences
4. Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance
5. Ardea Biosciences to Present at Two Upcoming Investor Conferences
6. Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results
7. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
8. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
9. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
10. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
11. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... quarter ended April 1, 2017 .   GAAP diluted ... to the prior year period as the sale of ... while non-GAAP diluted EPS of $0.50 increased 6.4%.  Revenue ... currency terms.  Excluding the effects of blood screening and ...
(Date:5/10/2017)... CSSi, the global leader in patient recruitment, ... is proud to announce the launch of its newly ... both enriched content and a customized layout that provides ... already well-established position as the top global patient recruitment ... months of hard work, we are delighted to officially ...
(Date:5/9/2017)...  Semler Scientific, Inc. (OTCQB: SMLR), an emerging ... the clinical effectiveness and efficiency of healthcare providers, ... ended March 31, 2017. "We ... identify when preventive care options are appropriate, which ... attacks or strokes occur," said Doug Murphy-Chutorian ...
Breaking Medicine Technology:
(Date:5/21/2017)... ... May 20, 2017 , ... Pot. Reefer. Grass. Mary Jane. ... it, and share its attributes like never before. More than a map, new social ... enthusiasts to stores, strains, products – and for the first time – each other. ...
(Date:5/21/2017)... (PRWEB) , ... May 21, 2017 , ... ... if it's been longer than six months since you've seen a dentist, it's ... twice per year and getting x-rays once per year. , Dental checkups are ...
(Date:5/19/2017)... Vermont (PRWEB) , ... May 19, 2017 , ... Springfield, ... its company blog. Titled " Ten Good Reasons To Hire An Experienced Personal Injury ... to make following an accident or injury. As the article says. if someone is ...
(Date:5/19/2017)... , ... May 19, 2017 , ... As a groundbreaking ... knows the importance of prostate cancer screenings. Early detection of the disease, he says, ... robotic surgery at Georgia Urology , stands alongside the Georgia Comprehensive Cancer Control’s ...
(Date:5/18/2017)... ... May 18, 2017 , ... Dr. Kim Ross supports Stroke Awareness Month by ... the link between this condition and serious systemic health conditions including heart disease and ... in Annapolis, MD, and seeking treatment with Dr. Ross immediately may prevent bacteria ...
Breaking Medicine News(10 mins):